Biotech Values

[ghmm]

ViRexx ... but think the company is cheap enough that a win in the OvaRex trials will make investors some money.
I agree with you. I think UTHR will do very well as well with OvaRex plus there is the Remodulin franchise so that's where my money is.

I was surprised that ViRexx didn't get some of the jump some of the other companies got following the DNDN panel outcome. Maybe because of all the other problems at the company and the fact that OvaRex isn't on too many people's radar screen. The IMPACT trials are PFS not overall survival too for what its worth.